Q4 2025 ACADIA Pharmaceuticals Inc Earnings Call Transcript
Key Points
- ACADIA Pharmaceuticals Inc (ACAD) achieved adjusted total revenues of $298 million in the fourth quarter, marking a 16% increase from the previous year.
- For the first time in the company's history, annual revenues exceeded $1 billion, reaching $1.08 billion in adjusted 2025 revenue, representing a 14% growth from the prior year.
- New Placid net sales were $189 million in the fourth quarter and $692 million for the full year, showing a 17% and 15% increase respectively.
- Debut net product sales reached $110 million in the fourth quarter and $391 million for 2025, with year-over-year sales growth of 13% and 12% respectively.
- The company has a robust R&D pipeline with four unique molecules targeting large addressable markets, with a combined full peak sales potential of $11 billion.
- ACADIA Pharmaceuticals Inc (ACAD) faced higher-than-anticipated Inflation Reduction Act invoices from CMS, requiring a non-recurring accounting change in estimates.
- The company received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) regarding their trofinetide marketing application in the EU.
- The 2026 guidance for debut does not include potential commercial sales from EU regulatory approval due to the current status of the application.
- SG&A expenses increased to $156 million in the fourth quarter, up from $130 million in the same quarter of 2024, driven by increased marketing investments.
- The company anticipates a significant increase in R&D expenses for 2026, primarily due to an increase in clinical and personnel costs as they advance their R&D portfolio.
Thank you for standing by. My name is JL and I will be your conference operator today. At this time, I would like to welcome everyone to the Acadia Pharmaceuticals Incorporated 4th quarter earnings call.
All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session.
If you would like to ask a question during this time, simply press star, followed by the number one on your telephone keypad.
If you would like to withdraw your question, simply press one again.
I would now like to turn the conference over to Al Kildani, senior Vice President of Investor relations and corporate communications. You may begin.
Good afternoon and thank you for joining us on today's hall to discuss Acadia's 4th quarter and full year 2025 financial results.
Joining me on the call today from Acadia are Catherine Owen Adams, our Chief Executive
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
